Fumonisin toxicity and sphingolipid biosynthesis

A. H. Merrill, E. Wang, T. R. Vales, E. R. Smith, J. J. Schroeder, D. S. Menaldino, C. Alexander, H. M. Crane, J. Xia, D. C. Liotta, F. I. Meredith, R. T. Riley

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Fumonisins are inhibitors of sphinganine (sphingosine) N-acyltransferase (ceramide synthase) in vitro, and exhibit competitive-type inhibition with respect to both substrates of this enzyme (sphinganine and fatty acyl-CoA). Removal of the tricarballylic acids from fumonisin B1 reduces the potency by at least 10 fold; and fumonisin A1 (which is acetylated on the amino group) is essentially inactive. Studies with diverse types of cells (hepatocytes, neurons, kidney cells, fibroblasts, macrophages, and plant cells) have established that fumonisin B1 not only blocks the biosynthesis of complex sphingolipids; but also, causes sphinganine to accumulate. Some of the sphinganine is metabolized to the 1-phosphate and degraded to hexadecanal and ethanolamine phosphate, which is incorporated into phosphatidylethanolamine. Sphinganine is also released from cells and, because it appears in blood and urine, can be used as a biomarker for exposure. The accumulation of these bioactive compounds, as well as the depletion of complex sphingolipids, may account for the toxicity, and perhaps the carcinogenicity, of fumonisins.

Original languageEnglish
Pages (from-to)297-306
Number of pages10
JournalAdvances in Experimental Medicine and Biology
Volume392
StatePublished - Mar 18 1996
Externally publishedYes

Fingerprint

Fumonisins
Sphingolipids
Biosynthesis
Toxicity
Sphingosine N-Acyltransferase
Acyl Coenzyme A
Macrophages
Plant Cells
Biomarkers
Fibroblasts
Neurons
Hepatocytes
Blood
Phosphates
safingol
Urine
Kidney
Substrates
Enzymes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Merrill, A. H., Wang, E., Vales, T. R., Smith, E. R., Schroeder, J. J., Menaldino, D. S., ... Riley, R. T. (1996). Fumonisin toxicity and sphingolipid biosynthesis. Advances in Experimental Medicine and Biology, 392, 297-306.

Fumonisin toxicity and sphingolipid biosynthesis. / Merrill, A. H.; Wang, E.; Vales, T. R.; Smith, E. R.; Schroeder, J. J.; Menaldino, D. S.; Alexander, C.; Crane, H. M.; Xia, J.; Liotta, D. C.; Meredith, F. I.; Riley, R. T.

In: Advances in Experimental Medicine and Biology, Vol. 392, 18.03.1996, p. 297-306.

Research output: Contribution to journalArticle

Merrill, AH, Wang, E, Vales, TR, Smith, ER, Schroeder, JJ, Menaldino, DS, Alexander, C, Crane, HM, Xia, J, Liotta, DC, Meredith, FI & Riley, RT 1996, 'Fumonisin toxicity and sphingolipid biosynthesis', Advances in Experimental Medicine and Biology, vol. 392, pp. 297-306.
Merrill AH, Wang E, Vales TR, Smith ER, Schroeder JJ, Menaldino DS et al. Fumonisin toxicity and sphingolipid biosynthesis. Advances in Experimental Medicine and Biology. 1996 Mar 18;392:297-306.
Merrill, A. H. ; Wang, E. ; Vales, T. R. ; Smith, E. R. ; Schroeder, J. J. ; Menaldino, D. S. ; Alexander, C. ; Crane, H. M. ; Xia, J. ; Liotta, D. C. ; Meredith, F. I. ; Riley, R. T. / Fumonisin toxicity and sphingolipid biosynthesis. In: Advances in Experimental Medicine and Biology. 1996 ; Vol. 392. pp. 297-306.
@article{14b11237753d4399aa47065d6b4ca514,
title = "Fumonisin toxicity and sphingolipid biosynthesis",
abstract = "Fumonisins are inhibitors of sphinganine (sphingosine) N-acyltransferase (ceramide synthase) in vitro, and exhibit competitive-type inhibition with respect to both substrates of this enzyme (sphinganine and fatty acyl-CoA). Removal of the tricarballylic acids from fumonisin B1 reduces the potency by at least 10 fold; and fumonisin A1 (which is acetylated on the amino group) is essentially inactive. Studies with diverse types of cells (hepatocytes, neurons, kidney cells, fibroblasts, macrophages, and plant cells) have established that fumonisin B1 not only blocks the biosynthesis of complex sphingolipids; but also, causes sphinganine to accumulate. Some of the sphinganine is metabolized to the 1-phosphate and degraded to hexadecanal and ethanolamine phosphate, which is incorporated into phosphatidylethanolamine. Sphinganine is also released from cells and, because it appears in blood and urine, can be used as a biomarker for exposure. The accumulation of these bioactive compounds, as well as the depletion of complex sphingolipids, may account for the toxicity, and perhaps the carcinogenicity, of fumonisins.",
author = "Merrill, {A. H.} and E. Wang and Vales, {T. R.} and Smith, {E. R.} and Schroeder, {J. J.} and Menaldino, {D. S.} and C. Alexander and Crane, {H. M.} and J. Xia and Liotta, {D. C.} and Meredith, {F. I.} and Riley, {R. T.}",
year = "1996",
month = "3",
day = "18",
language = "English",
volume = "392",
pages = "297--306",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Fumonisin toxicity and sphingolipid biosynthesis

AU - Merrill, A. H.

AU - Wang, E.

AU - Vales, T. R.

AU - Smith, E. R.

AU - Schroeder, J. J.

AU - Menaldino, D. S.

AU - Alexander, C.

AU - Crane, H. M.

AU - Xia, J.

AU - Liotta, D. C.

AU - Meredith, F. I.

AU - Riley, R. T.

PY - 1996/3/18

Y1 - 1996/3/18

N2 - Fumonisins are inhibitors of sphinganine (sphingosine) N-acyltransferase (ceramide synthase) in vitro, and exhibit competitive-type inhibition with respect to both substrates of this enzyme (sphinganine and fatty acyl-CoA). Removal of the tricarballylic acids from fumonisin B1 reduces the potency by at least 10 fold; and fumonisin A1 (which is acetylated on the amino group) is essentially inactive. Studies with diverse types of cells (hepatocytes, neurons, kidney cells, fibroblasts, macrophages, and plant cells) have established that fumonisin B1 not only blocks the biosynthesis of complex sphingolipids; but also, causes sphinganine to accumulate. Some of the sphinganine is metabolized to the 1-phosphate and degraded to hexadecanal and ethanolamine phosphate, which is incorporated into phosphatidylethanolamine. Sphinganine is also released from cells and, because it appears in blood and urine, can be used as a biomarker for exposure. The accumulation of these bioactive compounds, as well as the depletion of complex sphingolipids, may account for the toxicity, and perhaps the carcinogenicity, of fumonisins.

AB - Fumonisins are inhibitors of sphinganine (sphingosine) N-acyltransferase (ceramide synthase) in vitro, and exhibit competitive-type inhibition with respect to both substrates of this enzyme (sphinganine and fatty acyl-CoA). Removal of the tricarballylic acids from fumonisin B1 reduces the potency by at least 10 fold; and fumonisin A1 (which is acetylated on the amino group) is essentially inactive. Studies with diverse types of cells (hepatocytes, neurons, kidney cells, fibroblasts, macrophages, and plant cells) have established that fumonisin B1 not only blocks the biosynthesis of complex sphingolipids; but also, causes sphinganine to accumulate. Some of the sphinganine is metabolized to the 1-phosphate and degraded to hexadecanal and ethanolamine phosphate, which is incorporated into phosphatidylethanolamine. Sphinganine is also released from cells and, because it appears in blood and urine, can be used as a biomarker for exposure. The accumulation of these bioactive compounds, as well as the depletion of complex sphingolipids, may account for the toxicity, and perhaps the carcinogenicity, of fumonisins.

UR - http://www.scopus.com/inward/record.url?scp=9044222880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044222880&partnerID=8YFLogxK

M3 - Article

C2 - 8850625

AN - SCOPUS:9044222880

VL - 392

SP - 297

EP - 306

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -